About Broadview Ventures
Broadview Ventures is a venture capital firm founded in 2000. It is primarily based out of Boston, United States. As of Jun 2025, Broadview Ventures is an active investor, having invested in 57 companies, with 1 new investment in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Series A round of Mosanna Therapeutics Overall, Broadview Ventures portfolio has seen 7 IPOs and 8 acquisitions including key companies like Boston Scientific, Cogent and Lyra Therapeutics. A lot of funds co-invest with Broadview Ventures, with names like Viva BioInnovator sharing a substantial percentage of its portfolio. Broadview Ventures has team of 26 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 4 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Broadview Ventures' List of Top Investments
Broadview Ventures has a portfolio of 57 companies. Their most notable investments are in Corflow and Relief Cardiovascular.Their portfolio spans across United States, Switzerland, Canada and 6 more locations. They have invested in Life Sciences, HealthTech, High Tech and 4 other sectors, across stages such as Series A, Seed and 4 more. Here is the list of top investments by Broadview Ventures:Boston Scientific is a worldwide developer, manufacturer, and marketer of medical devices. Their products and technologies are used to diagnose or treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women's health, and chronic pain conditions. The devices include access devices, artificial sphincters, balloons, band ligators, catheters, defibrillators, guidewires, leads, needles, probes, and stents among others. It also develops surgical devices for minimally invasive surgery. Boston Scientific went public in May 1992. In 2022, the company recorded annual revenues of $12.68B and a net profit of $0.69B.
Key facts about Boston Scientific
- Founded Year: 1979
- Location: Marlborough (United States)
- Annual Revenue: $16.7B as on Dec 31, 2024
- Stage: Public
- Employee Count: 53,388 as on Mar 31, 2026
- Investors: JANA Partners, S Ventures and 8 Others
- Latest Funding Round: Grant (prize money), Dec 01, 2022, $*****
- Highlight: Public
2. Cogent
Cogent Communications group's network is designed to transmit data using IP and delivers services primarily to small and medium-sized businesses and communications service providers. Cogent provides on net services and Colocation services to customers through its own facilities. They also provide on-net Internet access to certain bandwidth-intensive users, such as universities, other Internet service providers (ISPs) and commercial content providers.
Key facts about Cogent
- Founded Year: 1999
- Location: Washington, DC (United States)
- Annual Revenue: $348M as on Dec 31, 2013
- Stage: Public
- Total Funding till date: $116M
- Employee Count: 2,859 as on Mar 31, 2026
- Investors: Worldview Technology Partners, Herald Investment Management and 13 Others
- Latest Funding Round: Post IPO, Jun 19, 2003, $*****
- Highlight: Public
Transforming cardiac rhythm management with innovative extravascular pacing and defibrillation solutions. This medical device company is dedicated to designing novel extravascular leads and deployment systems, aiming to eliminate the risks and drawbacks of traditional transvenous leads. They focus on both pacing and defibrillation solutions, offering a new option for pacing without entering the heart and life-saving ICD benefits without transvenous leads. Their extravascular solutions place leads outside the vasculature and heart, maintaining the integrity of the heart while delivering much-needed therapy. They are developing the EV Temporary Pacing Lead System and the EV-ICD Lead System, both designed to address pacing and defibrillation needs without entering the heart or vascular system. This innovative approach seeks to reduce complications associated with transvenous leads and improve patient outcomes in cardiac rhythm management. They are focused on medical devices, electrophysiology, cardiology, temporary pacing, extracardiac, and extravascular solutions.
Key facts about AtaCor Medical
- Founded Year: 2014
- Location: San Clemente (United States)
- Stage: Series D
- Total Funding till date: $137M
- Employee Count: 33 as on Mar 31, 2026
- Investors: aMoon, Broadview Ventures and 7 Others
- Latest Funding Round: Series D, Oct 06, 2025, $*****
- Highlight: Editors' Pick
Biotechnology firm innovating localized therapies for chronic rhinosinusitis (CRS). The company focuses on developing innovative therapies for the localized treatment of CRS, an inflammatory disease affecting millions. They leverage expertise in materials science, drug development, and formulation to create proprietary technology. This technology delivers medicines directly and consistently to affected tissues for sustained periods with a single administration. Their product candidates are bioabsorbable nasal implants designed for in-office administration, delivering continuous drug therapy to the sinonasal passages. The aim is to provide long-acting medication directly to sinonasal tissues inaccessible with conventional approaches, breaking the cycle of medical management for this underserved population. This approach integrates anti-inflammatory medication and advanced materials engineering to create a treatment solution.
Key facts about Lyra Therapeutics
- Founded Year: 2005
- Location: Watertown (United States)
- Annual Revenue: $1.56M as on Dec 31, 2023
- Stage: Public
- Total Funding till date: $110M
- Employee Count: 34 as on Mar 31, 2026
- Investors: HTIF, RA Capital Management and 9 Others
- Latest Funding Round: Post IPO, Jun 09, 2023, $*****
- Highlight: Public
Developer of medicines for patients with serious and rare diseases. The company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Key facts about Viridian Therapeutics
- Founded Year: 2007
- Location: Boulder (United States)
- Annual Revenue: $302K as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $14.5M
- Employee Count: 94 as on Dec 31, 2023
- Investors: Longitude Capital, Broadview Ventures and 1 Other
- Latest Funding Round: Series A, Feb 03, 2015, $*****
- Highlight: Public
Broadview Ventures' Year-on-Year Investment Trends
Broadview Ventures has invested in 57 companies over the last 26 years, with an average of 2 new investments annually in the last 10 years. In 2025, it made 3 investments. Its most recent first time investment was in Mosanna Therapeutics and most recent follow-on round was in HAYA Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 2 | 1 | 3 |
2024 | 4 | 3 | 7 |
2023 | 0 | 0 | 0 |
2022 | 4 | 3 | 7 |
2021 | 3 | 1 | 4 |
2020 | 1 | 1 | 2 |
2019 | 3 | 0 | 3 |
2018 | 2 | 0 | 2 |
2017 | 1 | 0 | 1 |
Broadview Ventures' Investments by Stage
Broadview Ventures is primarily an Early Stage Investor investor majorly investing in Series A (20) rounds where average round size is $355M, Seed (6) rounds where average round size is $28M and Series C (4) rounds where average round size is $103M.Stage of entry | No. of Investments |
|---|---|
Series A | 20 |
Seed | 6 |
Series C | 4 |
Series B | 3 |
PE | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Broadview Ventures' Investments by Sector
Broadview Ventures has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, HealthTech and Internet of Things - Industry Applications. Notably, it has invested in 48 Tech companies, 47 Enterprise (B2B) companies, 15 Tech hardware companies and at least 12 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 32 |
High Tech | 5 |
Enterprise Applications | 3 |
HealthTech | 3 |
Internet of Things - Industry Applications | 3 |
Others | 1 |
Note: We have considered here, only first round of investments
Broadview Ventures' Investments by Geography
Broadview Ventures has made most investments in United States (23), followed by Switzerland where it has made 3 investments.Country | No. of Investments |
|---|---|
United States | 23 |
Switzerland | 3 |
Canada | 2 |
Denmark | 2 |
Israel | 2 |
Others | 3 |
Note: We have considered here, only first round of investments
Broadview Ventures' recent investments
Broadview Ventures has not made any investment in 2026 so far.Here are the most recent investments by Broadview Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 09, 2025 | Switzerland | Series A | 3940 | [+6] | |
May 08, 2025 | Switzerland | Series A | 3638 | [+10] | |
Jan 08, 2025 | United States | Series A | 3902 | [+2] | |
Dec 19, 2024 | United States | Series C | 6358 | [+6] | |
Dec 03, 2024 | Denmark | Series A | 6003 | [+5] |
IPOs and Publicly Listed companies in Broadview Ventures' Portfolio
7 of Broadview Ventures' portfolio companies have become public. Lyra Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in May 2020 at marketcap of $198M and MiRagen got listed on the Nordic and Baltic regions (NASDAQ OMX) at marketcap of $45.6M.Here are Broadview Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 01, 2020 | Jun 18, 2015 | Series C | 6331 | |
Jun 20, 2014 | Jun 02, 2009 | Series A | 9500 | |
Jun 20, 2014 | - | - | 1515 | |
Jun 04, 2014 | - | - | 2139 | |
Feb 26, 2007 | Dec 18, 2010 | Post IPO | 8252 |
Acquired companies in Broadview Ventures' Portfolio
8 companies from Broadview Ventures' portfolio have been acquired. The most recent acquisition were Pulmokine in Dec 2024 by XOMA Corporation.Here are Broadview Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 02, 2024 | Mar 03, 2015 | Series A | 5947 | |
Jun 01, 2023 | Mar 07, 2018 | Series B | 6276 | |
Dec 14, 2022 | - | - | 2933 | |
Sep 20, 2022 | Aug 14, 2019 | Series A | 7252 | |
Oct 02, 2017 | Sep 16, 2013 | Series A | 7340 |
Team profile of Broadview Ventures
Broadview Ventures has a team of 26 members including 3 Partners and 1 Principal located in United States. Broadview Ventures' team does not sit on the board of any company as of now.Here is a list of top team members in Broadview Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Boston | - | - | |
Partner | Boston | - | - | |
Partner | - | - | - | |
Principal | Boston | - | - |
Co-investors of Broadview Ventures
Over the past 26 years, 228 investors have co-invested in Broadview Ventures's portfolio companies. This includes funds and angels.
- Invested before Broadview Ventures: HHS, MassChallenge and 37 others have invested in rounds before Broadview Ventures. There are 6 companies where HHS has invested before Broadview Ventures and 2 companies where MassChallenge has invested before Broadview Ventures.
- Top Co-investors of Broadview Ventures: 85 investors entered a company along with Broadview Ventures. These include investors like Viva BioInnovator (2 companies).
- Invested after Broadview Ventures: A total of 104 investors have invested in Broadview Ventures's portfolio after their investments. Top Investors include Europa (3 companies), Longview Partners (2 companies) and Perceptive Advisors (2 companies).
Recent News related to Broadview Ventures
•
Mosanna Therapeutics Launches with $80 Million for Obstructive Sleep Apnea Nighttime Nasal SprayPR Newswire•Jun 09, 2025•Mosanna Therapeutics, Pivotal Life Sciences, EQT, Broadview Ventures and 2 others
•
Relief Cardiovascular Raises $12M in Series A FinancingFinSMEs•Jan 08, 2025•Relief Cardiovascular, Broadview Ventures, Advent Life Sciences, Pacific Health Ventures and 1 other
•
•
CorFlow Therapeutics AG’s €44 Million Series B Financing RoundGlobal Legal Chronicle•Sep 19, 2024•Corflow, Walder Wyss, Broadview Ventures, Panakes Partners
•
CorFlow Therapeutics AG Completes €44 Million Series B Financing to Support the Advancement of a Novel Diagnostic and Drug Delivery Platform for Microvascular Obstruction (MVO) in Heart Attack PatientsFinancial Post•Sep 10, 2024•Corflow, Broadview Ventures, Panakes Partners, 415 CAPITAL and 9 others
•
MedTech & Irrus Syndicates Lead Study Funding for CroiValve's Transcatheter Tricuspid DeviceMedical Product Outsourcing•Sep 05, 2024•CroiValve, MedTech Syndicates, Ascentifi, Broadview Ventures and 2 others
•
Croívalve Announces $16 Million Equity Financing To Fund Us Early Feasibility Study Of Novel Transcatheter Tricuspid DeviceBusiness Wire•Aug 07, 2024•CroiValve, MedTech Syndicates, Ascentifi, Furthr and 9 others
•
AtaCor Medical closes $28 million Series C financingG-MedTech•Apr 25, 2024•AtaCor Medical, Arboretum Ventures, Broadview Ventures, Hatteras Venture Partners and 2 others
•
•
